Asset
RETIFANLIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04082364 | phase2_3 | completed | 2019-09-30 | 2024-01-15 | MacroGenics | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer |
| NCT04129320 | phase2_3 | withdrawn | 2019-10-01 | 2020-10-01 | MacroGenics | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck |
| NCT04634825 | phase2 | terminated | 2021-03-17 | 2022-07-29 | MacroGenics | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer |
| NCT03531632 | phase1_2 | completed | 2018-06-04 | 2020-02-08 | MacroGenics | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer |
| NCT03406949 | phase1 | completed | 2018-02-27 | 2022-04-27 | MacroGenics | MGD009/MGA012 Combination in Relapsed/Refractory Cancer |
FDA applications (0)
This company has no applications containing this asset.